Overall mortality and causes of death during the COVID-19 pandemic and vaccination campaign in Germany (REVIEW)
Main Article Content
Abstract
This analysis investigates mortality and relevant causes of death in Germany between 2019 and 2023, focusing particularly on the consequences of the SARS-CoV2 pandemic and mass vaccination campaigns.
Official, freely accessible annual statistics and government reports were used as sources to provide an overview of how the annual raw data has developed.
No `excess mortality` due to the pandemic in 2020 was detected that exceeded the level of the increase in deaths during the 2015 flu epidemic.
The years following the pandemic were characterised by widespread vaccination with spike-based mRNA-vaccines and basic immunisation rates exceeding 70%. Contrary to expectations, however, overall mortality increased by 3.797% in 2021 and by a further 4.31% in 2022 compared to the previous year. This represented an increase of 8.85% and 13.54% respectively compared to the pre-pandemic year. Even though the profile of the Covid-19 disease became less dangerous in the 2021 vaccination year and in the years that followed, the number of recorded deaths from the disease rose alarmingly (to 183.74% in 2021).
The available data suggest that overall mortality increased in 2021 and 2022, although the number of recorded Covid-19 deaths began to decline as early as 2022. There was a shift in the spectrum of causes of death, with an increase in fatal cardiovascular diseases, mental illnesses, and disorders of the nervous and digestive systems, and a decrease in respiratory diseases.
Given the profound mode of action of spike-based mRNA vaccines and their considerable potential for side effects, it is reasonable to suggest that they may contribute to the multifactorial causes of increased mortality.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS et al. Extrapulmonary manifestations of COVID-19. Nat Med 2020; 26: 1017-1032
3. Lehmann KJ. Suspected Causes of the Specific Intolerance Profile of Spike-Based Covid-19 Vaccines (Review/Analysis) Medical Research Archives, [online] 2024; 12(9)
4. Changeux JP, Amura Z, Rey FA, Miyara M. A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications. Comptes Rendus Biologies 2020; 343/1: 33-39
5. Chaurasia B, Chavda V, Lu B, Garg K, Montemurro N. Cognitive deficits and memory impairments after Covid-19 (Covishield) vaccination. Brain Behav Immun Health 2022; 22: 100463
6. Lehmann Lehmann KJ. Spike-Induced Disturbances (SPAS*): An Analysis of Common Suspected Adverse Experiences Associated with Covid-19 Vaccines. I J Infectious Disea 2022; 3(1): 1-19
7. Thorp J, Rogers C, Cosgrove K, Hatfill St, Breggin P, Pinsky D et al. Association between COVID-19 Vaccination and Neuropsychiatric Conditions. PrePrints.Org 2025; doi: 10.20944/preprints 202504.1099.v1
8. Carlson EC, Macsai M, Bertrand S, Bertrand D and Nau J: The SARS-CoV-2 Virus and the Cholinergic System: Spike Protein Interaction with Human Nicotinic Acetylcholine Receptors and the Nicotinic Agonist Varenicline Int. J. Mol. Sci. 2023; 24(6), 5597; https://doi.org/10.3390/ijms24065597
9. Oliveira SF, Ibarra AA, Bermudez I, Casalino L Gaieb Z, Shoemark DK et al. A potential interaction between the SARS-CoV-2 spike protein and nicotinic acetylcholine receptors. Biophysical Journal 2021; 120/6: 983-993
10. Tillman TS, Chen Q, Bondarenko V, Coleman JA, Xu Y, Tang P. SARS-CoV-2 Spike Protein Downregulates Cell Surface α7nAChR through a Helical Motif in the Spike Neck. ACS Chemical Neuroscience 2023; 14/4
11. Leitzke M. Is the post-Covid-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration? Bioelectronic Medicine 2023; 9:2
12. O’Brien BCV, Weber L, Hueffer K, Weltzin M. SARS-CoV-2 spike ectodomain targets α7 nicotinic acetylcholine receptors. Biol Chem. 2023; 299(5):104707.
13. Täglicher Lagebericht des RKI zur Coronavirus-Krankheit-2019
14. www-genesis.destatis.de/datenbank/online/statistic /23211/table/23211-0001
15. Mentzer D, Oberle D, Streit R, Weisser K, Keller-Stanislawski B: Sicherheitsprofil der COVID-19-Impfstoffe – Sachstand 31.03.2023 BfArM/PEI, Ausgabe 2, Juni 2023
16. www.bfarm.de/DE/Aktuelles/Publikationen/Bulletin/Ausgaben/2025/1-2025.html?nn=594982 März 2025
17. https://www.rki.de/DE/Aktuelles/Publikationen/Epidemiologisches-Bulletin/2021/50_21.pdf?__blob=publicationFile&v=1
18. https://de.statista.com/statistik/daten/studie/1013303/umfrage/sterberate-in-deutschland/
19. Eder G (20.1.2025): https://www.mwgfd.org/2025/01/vermiedene-und-verursachte-todesfaelle-die-zwei-seiten-der-corona-impfung/
20. Radtke R: Influenza assoziierte Sterblichkeit bis 2024 (08.11.2024 ) https://de.statista.com/statistik/daten/studie/405363/umfrage/influenza-assoziierte-uebersterblichkeit-exzess-mortalitaet-in-deutschland/
21. https://de.statista.com/statistik/daten/studie/1217/umfrage/entwicklung-der-gesamtbevölkrung-seit-2002/
22. Lehmann K. (8.3.2021): Rezeptorvermittelte Wirkungen von Spike-Proteinen und SARS-CoV-2 https://karla-lehmann.de/medizin-gesellschaft/page/6/
23. Lehmann K. (24.3.2021): Der Doppelcharakter Spike-exprimierender Impfstoffe - Eine Analyse der Verträglichkeit. https://karla-lehmann.de/medizin-gesellschaft/page/6/
24. Lehmann K. Das Impfjahr 2021 (30.11.2021) https://karla-lehmann.de/medizin-gesellschaft/page/4/
25. Lehmann KJ. Suspected Cardiovascular Side Effects of two COVID-19 Vaccines JBTW 2021; 10/5: 001-006
26. Lehmann KJ. The Global and Specific Cardiovascular Burden of Spike-based COVID-19 Vaccination. Int J Cardiol Res 2023; 12:5
27. Lehmann K. https://tkp.at/2025/02/03/die-scheinwelt-der-sicheren-spike-basierten-covid-19-impfungen/
28. Streit R, Mentzer D. Pharmakovigilanz von Impfstoffen aus den Jahren 2022 und 2023, Bulletin zur Arzneimittelsicherheit, BfArM/PEI, Ausgabe 3, September 2024
29. Impfdashbord.de des RKI/BMG (22.4.2025)
30. Perez JC, Montagnier L. Heat wave, excess mortality and Covid19 vaccination: the case of 31 European countries in 2022. Available from: https://www.researchgate.net/publication/363701046_Heat_wave_excess_mortality_and_Covid19_vaccination_the_case_of_31_European_countries_in_2022 [accessed Nov 18 2022].
31. Hegarty P. Excess Mortality and the Effect of the COVID-19 Vaccines Part 1: European Data (2023). doi: 10.20944/preprints202309.0674.v2
32. Hegarty P. Excess Mortality and the Effect of the COVID-19 Vaccines Part 2: Global data (2024). https://www.researchgate.net/publication/379815723
33. Ioannides JPA. Infection fatality rate of COVID-19 inferred from seroprevalence data. Bull World Health Organ 2021; 99:19–33F
34. Streeck H, Schulte B, Kümmerer BM, Richter E, Höller T, Fuhrmann Ch, et al. Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany. Nature Comm 2020; 11: 5829
35. Covid-19 Forecasting Team: Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis. Lancet 2022; 399: 1469-88